Immunotherapy is a rapidly expanding mainstay in the cancer treatment regimen where bispecific antibodies currently represent a $10Bn market and have experienced a CAGR of 118% through 2019 (Kuick Research – Feb 2020).
Most prominently, blinatumomab has shown dramatic efficacy in treatment of adult acute lymphoblastic leukemia (ALL). However, the antibody requires cumbersome administration and faces toxicity issues such as cytokine release syndrome (CRS).
New technologies are expected to overcome the limitations of the first generation T cell engagers, however all require recombinant DNA technology to combine the two requisite antibody binding domains together into the final therapeutic drug. Synaffix has taken a much simpler and faster non-genetic approach to combining the two binding domains covalently, following independent expression.